facebook button SeaGen: Brentuximab Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Seagen: Brentuximab Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Sponsor: Seagen

Double blinded study investigating the efficacy of Brentuximab Vedotin in conjunction with Rituximab and Lenalidomide to treat patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL).